Tuesday, May 24, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Evaluating immunogenicity after BNT162b2 booster vaccination

by Medical Finance
in Coronavirus
Study: Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers. Image Credit: Steve Heap/Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the Research Square* preprint server, researchers assessed the levels of immunoglobulin (Ig) G and IgA antibodies in sera samples from healthcare workers (HCW) before vaccination, after the first vaccine dose, after eight months of the first dose, and after receiving the booster shot.

Study: Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers. Image Credit: Steve Heap/Shutterstock
Study: Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers. Image Credit: Steve Heap/Shutterstock

Background

It is crucial to evaluate the waning of the immune response in HCW, a high-risk population that remains constantly in touch with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients.

The world has entered the third year of the coronavirus disease 2019 (COVID-19) pandemic, yet there is no one specific treatment for this deadly infection. Therefore, vaccinations and developing herd immunity are the only effective means to mitigate the adverse effects of COVID-19.

In this scenario, monitoring HCW characteristics and their response to vaccination presents an opportunity to examine vaccine efficacy (VE), extrapolate it to a larger population, and guide public health decisions.

About the study

In the current study, researchers enrolled 103 HCW vaccinated with the BNT162b2 vaccine in January 2021. The test subjects comprised mainly females with an average age of 40.26 years. They had several comorbidities, including obesity, allergies, diabetes, hypothyroid, and cardiovascular diseases.

The researchers followed up with the test subjects before and after vaccination between May 2020 and October 2021 for evaluating the serum IgG and IgA levels at different time points – immediately after primary vaccination, at the eight month-follow-up, before the third booster dose, and up to three weeks of receiving the booster dose.

The team performed an enzyme-linked immunosorbent assay (ELISA) to determine the serum levels of anti-SARS-CoV-2 IgG and IgA.

Study findings

All the test subjects had high IgG and IgA levels after receiving the first dose of the vaccine, irrespective of their infection status before vaccination. Moreover, age, gender, or pre-existing comorbidities did not alter the antibody response after vaccination. Therefore, further studies are warranted to ascertain the correlation of age and sex with the immune response induced by the BNT162b2 vaccination.

After eight months of the first round of vaccination (between January and October 2021), the mean IgG and IgA levels diminished by 2.4 times and 2.7 times, respectively. After the booster shot, IgG and IgA levels immediately increased 2.7 and 2.5 times, respectively. The IgG levels after booster vaccination were statistically higher than those obtained by the first vaccination; however, the IgA levels after the booster were comparable to those attained after the first vaccination.

In a study conducted on HCW in Germany, the researchers observed that SARS-CoV-2-specific IgM and IgA antibodies declined rapidly over time, whereas IgG decreased slowly. Moreover, previously SARS-CoV-2-infected subjects induced higher IgG levels and lesser IgA levels after booster vaccination. The study pointed out that the correlation between the total antibodies and their neutralizing capacity is not yet fully comprehended.

On the other hand, studies have demonstrated that the booster dose enhances both the quantity and quality of anti-SARS-CoV-2 antibodies, inducing significantly higher neutralizing titers than the titers obtained after the two-dose vaccination series.

In one of the cases, where there were no detectable IgG and IgA antibodies after eight months post-first vaccination, the booster shot rapidly induced high amounts of IgG and IgA antibodies within the first week. Both IgG and IgA levels continued to rise after two to three weeks of receiving the booster shot. Interestingly, the anti-S IgG antibodies surpassed the previously achieved antibody levels post the first dose of vaccination, suggesting a robust cellular memory.

Concerning adverse effects post-vaccination, the booster shot caused mild pain at the injection site in over 75% of the test subjects.

Nine subjects from the study group (8.73%) developed COVID-19 four months after the booster shot, demonstrating that genetically distinct new SARS-CoV-2 variants have the potential to evade the established immune memory.

Conclusions

Although knowledge regarding antibody and cellular persistence is sparse, the study highlighted the complex regulatory mechanisms that regulate the generation of immune memory after both natural infection and vaccination.

The third dose of the BNT162b2 vaccine (booster) addressed the issue of waning immunity and bypassed the inefficacy against SARS-CoV-2 variants initially; however, after five months, the immune protection elicited by the booster dose declined dramatically. Therefore, more clinical studies are required to verify its safety, evaluate its necessity, and ascertain whether there is a need for an additional dose after the booster shot.

*Important notice

Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: No magic bullet: limiting in-school transmission in the face of variable SARS-CoV-2 viral loads. Image Credit: Phuttharak/Shutterstock

Modeling SARS-CoV-2 transmission and the impact of control measures in schools

by Medical Finance
May 24, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers assessed the robustness and feasibility of a layered coronavirus...

Study: Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2. Image Credit: CROCOTHERY/Shutterstock

Investigating extensive SARS-CoV-2 neutralizing immunoglobulins from COVID-19 recovered subjects

by Medical Finance
May 24, 2022
0

A recent study posted to the bioRxiv* preprint server discovered immunoglobulins (Igs) with powerful broad-acting neutralizing capacity against severe acute respiratory...

Study: Long-term psychological consequences of long Covid: a propensity score matching analysis comparing trajectories of depression and anxiety symptoms before and after contracting long Covid vs short Covid. Image Credit: Starocean/Shutterstock

Study explores long-lasting psychological implications of long COVID

by Medical Finance
May 24, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated the long-standing psychological manifestations of long coronavirus disease (long...

Tau mapping offers potential treatment targets and biomarkers for dementia and Alzheimer disease

New laws let visitors see loved ones in health care facilities, even in an outbreak

by Medical Finance
May 24, 2022
0

Jean White’s mother has dementia and moved into a memory care facility near Tampa, Florida, just as coronavirus lockdowns began...

Study: Delta-Omicron recombinant SARS-CoV-2 in a transplant patient treated with Sotrovimab. Image Credit: ice_blue/Shutterstock

SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

by Medical Finance
May 24, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers described a case of co-infection with severe acute respiratory...

Study: SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein. Image Credit: Adao/Shutterstock

SARS-CoV-2 Omicron variant spike-specific unique cluster of differentiation cells

by Medical Finance
May 24, 2022
0

A recent article posted to the bioRxiv* preprint server presented a safe and efficient multi-epitope severe acute respiratory syndrome coronavirus 2...

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Image Credit: ArtemisDiana/Shutterstock
    Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants
  • Study: Elevated plasma Complement Factor H Regulating Protein 5 is associated with venous thromboembolism and COVID-19 severity. Image Credit: Nhemz/Shutterstock
    Role of complement factor H-related protein 5 in venous thromboembolism and COVID-19
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply